US Patent

US9446057 — Controlled release doxycycline

Method of Use · Assigned to Mayne Pharma International Pty Ltd · Expires 2034-12-23 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects controlled release compositions of doxycycline that exhibit a superior dissolution profile and reduce side effects such as nausea and irritation.

USPTO Abstract

The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.

Drugs covered by this patent

doxycycline-hyclate (DOXYCYCLINE HYCLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-918`	—	doxycycline-hyclate
`U-918`	—	doxycycline-hyclate

Patent Metadata

Patent number: US9446057
Jurisdiction: US
Classification: Method of Use
Expires: 2034-12-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Mayne Pharma International Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.